Sarepta and Catalent File Answers in REGENXBIO v. Sarepta Litigation
Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case
Samsung Files IPR Petition on Regeneron’s Aflibercept Patent
White House Announces “Bold Goals” for Biotech
Court Denies Amgen’s Motion to Dismiss and Motion to Stay Regeneron’s Antitrust Case
Chinese Market Biosimilar Update
BPCIA Aflibercept Litigation: Mylan Seeks Leave to Add a Declaratory Judgment Counterclaim of No Lost Profits or Injunctive Relief
Celltrion’s CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTIN
RELEUKO Receives FDA Approval
Subscribe: Subscribe via RSS
Blogs
Firm/Org